Skip to main content

GRFS · Grifols SA

Track GRFS — free
$8.15 -0.05 (-0.61%) At close · Nov 20
Market Cap
$5.55B
Shares
680.58M
Volume · Nov 20 848.3K Avg daily vol (3M) 622.34K

Price & Indicators

 

Key stats

Close
$8.15
Fri 20 Nov
Open
$8.10
Fri 20 Nov
Average volume, 30 days
732K
shares a session
Short interest
6.0M
0.9% of shares · 8.1 days to cover
Day range
$8.08$8.23
Open $8.10 Close $8.15
52-week closing range
$7.02$9.72
Close $8.15 16.2% under the high
Short volume, last session
31%
Last earnings
Nov 2, 2026
Price history
Jan 2020 to Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 2
Earnings call
Q3 adjusted EBITDA reaches €538 million; interim dividend €0.15

Grifols reported Q3 Biopharma growth of 10.3% and group revenue growth of 8.4%, both at constant currency, with adjusted EBITDA of €538 million and a 26.4% margin in the quarter. Total net leverage stood at 3.98x. The Board announced a 2026 interim dividend of €0.15 per share, payable in early December 2026.

5 source passages
Q3 was led by Biopharma, which grew 10.3%, supporting Group revenue growth of 8.4% - both at constant currency. That commercial performance, together with continued operating discipline, translated into adjusted EBITDA of €538 million and margin expansion to 26.4% in the quarter. Total net leverage stood at 3.98x and secured net leverage at 2.5x. has led the Board to announce a 2026 interim dividend of €0.15 per share. the Board has approved an interim dividend of 0.15 euros per share, payable in early December 2026. Open the document at this passage
Nov 2
Current report 6-K
Board approves €0.15 interim dividend per share, payable 4 December 2026

Grifols's board approved an interim dividend on account of 2026 profit of euro 0.15 per share, to be paid on 4 December 2026. Banco Bilbao Vizcaya Argentaria (BBVA) will act as paying agent.

3 source passages
the Board of Directors of Grifols, at its meeting held on 30 October 2026, has approved the payment of an interim dividend on account of the 2026 profit of euro 0.15 per each share Payment of the interim dividend will be made on 4 December 2026. The paying agent will be Banco Bilbao Vizcaya Argentaria (BBVA). Open the document at this passage
Nov 2
Current report 6-K
Q3 revenue rises 8.4%, net profit grows 27.9%

Grifols reported Q3 2026 revenue of EUR 2,040 million, up 8.4% year-over-year at constant currency, and net profit of EUR 162 million, up 27.9%, while confirming full-year 2026 guidance.

3 source passages
Revenue in the third quarter of 2026 reached EUR 2,040 million, up 8.4% year-over-year on a constant-currency (cc) basis, primarily driven by growth in the Biopharma business. Grifols’ net profit in the third quarter increased 27.9% compared with the prior-year quarter to EUR 162 million, bringing year-to-date net profit for the first nine months of the year to EUR 390 million, an increase of 28.4%. Grifols confirms its guidance for the full year 2026 following a first nine months performance in line with expectations. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+4.3%
Year over year
Operating margin
16.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
1.2%
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-3.3%
Trailing year
Short interest
0.9%
Latest settlement · 8.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg +4%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 42%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +8%
trailing
6-month return +7%
trailing
YTD return −13%
this year
Relative strength +16%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.88% of shares out · ▼ -14.5% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
168 holders — mid 3-yr range
Squeeze score 47
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 32%
annualized · 1-yr
Max drawdown −28%
past year
ATR 2.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 2, 2026
Adjusted EBITDA margin · full year 2026 Non-GAAP 25%
Previous outlook earlier release · from the Earnings Call filed Jul 28, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA margin · full year 2026 at least 25%
Egypt's contribution to ex-U.S. plasma collections · by 2029 50%
Adj EBITDA margin target · full year 2026 at least 25%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
42% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.88% of shares out · ▼ -14.5% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
168 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7 Now $8 · 42% Range high $10
vs 200-day avg +2% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GRFS
Grifols SA
this stock
$5.55B -12.8% — — 0.9%
LLY
ELI LILLY & Co
$1.27T +25.3% +44.7% 43.7 0.8%
JNJ
Johnson & Johnson
$651.11B +30.7% +6.0% 41.1 0.7%
ABBV
AbbVie Inc.
$505.89B +25.3% +8.6% 49.3 0.9%
MRK
Merck & Co., Inc.
$329.65B +27.0% +1.3% 137.9 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
168
% held
20.5%
Net QoQ
-3.0M sh
Top holder
BRANDES INVESTMENT PARTNE…
Held Float
View
Held by Funds
Fund positions
26
View
Short & Settlement
Short Interest Falling
Shares short
6.0M
Days to cover
8.1d
Change
-1.0M sh
View
Short Volume
Short vol %
31%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
510
Value
$3.7K
As of
Sep 24, 2026
View
Off-Exchange
Off-exchange %
33.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Mar 31, 2023
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 2, 2026
This year
14

Grifols reported Q3 2026 revenue of EUR 2,040 million, up 8.4% year-over-year at constant currency, and net profit of EUR 162 million, up 27.9%, while confirming full-year 2026 guidance.

View
Earnings & Events
Webcasts
Last webcast
Nov 2, 2026
View
Investor Relations
Latest news
Grifols increases revenue by 8.4%…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
GRFS -6.2% +7.8% +6.8% +0.6% -12.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +2.4% +17.0% +16.0% +9.3% -14.0%

Capital returns

Latest dividend
$0.094 / share · ex Jul 2, 2026
Declared · upcoming
$0.1686 / share · ex Dec 3, 2026
Cut 45.7%
Paid (TTM)
$0.094 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1438569 CUSIP 398438408 13F (30d) 181 filings 153 filers Visit website Investor relations